https://orcid.org/0000-0001-7650-123X
References
- Henderson-Smart DJ. The effect of gestational age on the incidence and duration of recurrent apnoea in newborn babies. Aust Paediatr J. 1981;17(4):273–276.
- Eichenwald EC, Zupancic JA, Mao WY, et al. Variation in diagnosis of apnea in moderately preterm infants predicts length of stay. Pediatrics. 2011;127(1):e53–e58.
- Dobson NR, Patel RM, Smith PB, et al. Trends in caffeine use and association between clinical outcomes and timing of therapy in very low birth weight infants. J Pediatr. 2014;164(5):992–998 e3.
- Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112–2121.
- Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2010;20(1):CD000273.
- Abdel-Hady H, Nasef N, Shabaan AE, et al. Caffeine therapy in preterm infants. World J Clin Pediatr. 2015;4(4):81–93.
- Davis PG, Schmidt B, Roberts RS, et al. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. J Pediatr. 2010;156(3):382–387.
- Patel RM, Leong T, Carlton DP, et al. Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol. 2013;33(2):134–140.
- Spitzer AR. Evidence-based methylxanthine use in the NICU. Clin Perinatol. 2012;39(1):137–148.
- Abdel Wahed MA, Issa HM, Khafagy SM, et al. Effect of caffeine on superior mesenteric artery blood flow velocities in preterm neonates. J Matern Fetal Neonatal Med. 2019;32(3):357–361.
- Lodha A, Seshia M, McMillan DD, et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr. 2015;169(1):33–38.
- Zubrow AB, Hulman S, Kushner H, et al. Determinants of blood pressure in infants admitted to neonatal intensive care units: a prospective multicenter study. Philadelphia Neonatal Blood Pressure Study Group. J Perinatol. 1995;15(6):470–479.
- Committee on Fetus and Newborn. American Academy of Pediatrics. Apnea, sudden infant death syndrome, and home monitoring. Pediatrics. 2003;111(4 Pt 1):914–917.
- Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2001;163(7):1723–1729.
- Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am. 1986;33(1):179–201.
- Katheria AC, Sauberan JB, Akotia D, et al. A pilot randomized controlled trial of early versus routine caffeine in extremely premature infants. Amer J Perinatol. 2015;32(09):879–886.
- Wei QZ, Su P, Han JT, et al. Effect of early caffeine treatment on the need for respirator therapy in preterm infants with respiratory distress syndrome. Zhongguo Dang Dai Er Ke Za Zhi. 2016;18(12):1227–1231.
- Amaro CM, Bello JA, Jain D, et al. Early caffeine and weaning from mechanical ventilation in preterm infants: a randomized, placebo-controlled trial. J Pediatr. 2018;196:52–57.
- Borszewska-Kornacka MK, Hozejowski R, Rutkowska M, et al. Shifting the boundaries for early caffeine initiation in neonatal practice: results of a prospective, multicenter study on very preterm infants with respiratory distress syndrome. PLoS One. 2017;12(12):e0189152.
- Taha D, Kirkby S, Nawab U, et al. Early caffeine therapy for prevention of bronchopulmonary dysplasia in preterm infants. J Matern Fetal Neonatal Med. 2014;27(16):1698–1702.
- Nylander Vujovic S, Nava C, Johansson M, et al. Confounding biases in studies on early- versus late-caffeine in preterm infants: a systematic review. Pediatr Res. 2020;88(3):357–364.